dc.contributor.author | Samson, A | |
dc.contributor.author | West, EJ | |
dc.contributor.author | Carmichael, J | |
dc.contributor.author | Scott, KJ | |
dc.contributor.author | Turnbull, S | |
dc.contributor.author | Kuszlewicz, B | |
dc.contributor.author | Dave, RV | |
dc.contributor.author | Peckham-Cooper, A | |
dc.contributor.author | Tidswell, E | |
dc.contributor.author | Kingston, J | |
dc.contributor.author | Johnpulle, M | |
dc.contributor.author | da Silva, B | |
dc.contributor.author | Jennings, VA | |
dc.contributor.author | Bendjama, K | |
dc.contributor.author | Stojkowitz, N | |
dc.contributor.author | Lusky, M | |
dc.contributor.author | Prasad, KR | |
dc.contributor.author | Toogood, GJ | |
dc.contributor.author | Auer, R | |
dc.contributor.author | Bell, J | |
dc.contributor.author | Twelves, CJ | |
dc.contributor.author | Harrington, KJ | |
dc.contributor.author | Vile, RG | |
dc.contributor.author | Pandha, H | |
dc.contributor.author | Errington-Mais, F | |
dc.contributor.author | Ralph, C | |
dc.contributor.author | Newton, DJ | |
dc.contributor.author | Anthoney, A | |
dc.contributor.author | Melcher, AA | |
dc.contributor.author | Collinson, F | |
dc.date.accessioned | 2022-05-04T08:57:34Z | |
dc.date.available | 2022-05-04T08:57:34Z | |
dc.date.issued | 2022-06-03 | |
dc.identifier.citation | Cancer immunology research, 2022 | |
dc.identifier.issn | 2326-6066 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5105 | |
dc.identifier.eissn | 2326-6074 | |
dc.identifier.eissn | 2326-6074 | |
dc.identifier.doi | 10.1158/2326-6066.cir-21-0171 | |
dc.identifier.doi | 10.1158/2326-6066.cir-21-0171 | |
dc.description.abstract | Improving the chances of curing patients with cancer who have had surgery to remove metastatic sites of disease is a priority area for cancer research. Pexa-Vec (Pexastimogene Devacirepvec; JX-594, TG6006) is a principally immunotherapeutic oncolytic virus that has reached late-phase clinical trials. We report the results of a single-center, nonrandomized biological end point study (trial registration: EudraCT number 2012-000704-15), which builds on the success of the presurgical intravenous delivery of oncolytic viruses to tumors. Nine patients with either colorectal cancer liver metastases or metastatic melanoma were treated with a single intravenous infusion of Pexa-Vec ahead of planned surgical resection of the metastases. Grade 3 and 4 Pexa-Vec-associated side effects were lymphopaenia and neutropaenia. Pexa-Vec was peripherally carried in plasma and was not associated with peripheral blood mononuclear cells. Upon surgical resection, Pexa-Vec was found in the majority of analyzed tumors. Pexa-Vec therapy associated with IFNα secretion, chemokine induction, and resulted in transient innate and long-lived adaptive anticancer immunity. In the 2 patients with significant and complete tumor necrosis, a reduction in the peripheral T-cell receptor diversity was observed at the time of surgery. These results support the development of presurgical oncolytic vaccinia virus-based therapies to stimulate anticancer immunity and increase the chances to cure patients with cancer. | |
dc.format | Print-Electronic | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | AMER ASSOC CANCER RESEARCH | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.title | Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2022-04-15 | |
rioxxterms.version | AM | |
rioxxterms.versionofrecord | 10.1158/2326-6066.cir-21-0171 | |
rioxxterms.licenseref.startdate | 2022-04-19 | |
dc.relation.isPartOf | Cancer immunology research | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/ImmNet | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy | |
pubs.publication-status | Published | |
pubs.embargo.terms | Not known | |
icr.researchteam | Targeted Therapy | |
dc.contributor.icrauthor | Harrington, Kevin | |
dc.contributor.icrauthor | Melcher, Alan | |